The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| GHRS | +68.75% | N/A | N/A | -30% |
| S&P | +18.54% | +92.9% | +14.04% | +58% |
GH Research Plc operates as a holding company, which engages in the provision of biopharmaceutical products and services. It develops therapeutic products for patients of psychiatric and neurological disorders. The firm develops novel and proprietary 5-Methoxy-N and N-Dimethyltryptamine, or 5-MeO-DMT, therapies. The company was founded by Theis Terwey, Florian Schönharting, and Magnus Halle in 2018 and is headquartered in Dublin, Ireland.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.08M | -5.1% |
| Market Cap | $756.12M | 24.6% |
| Market Cap / Employee | $15.12M | 0.0% |
| Employees | 50 | 2.0% |
| Net Income | -$9.29M | 10.5% |
| EBITDA | -$14.61M | -11.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $253.87M | 191.4% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.28M | -43.1% |
| Short Term Debt | $0.36M | 38.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -15.76% | -0.1% |
| Return On Invested Capital | -11.62% | 11.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$9.71M | 1.6% |
| Operating Free Cash Flow | -$9.64M | 2.2% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.75 | 1.92 | 3.21 | 2.44 | -15.72% |
| Price to Tangible Book Value | 1.75 | 1.92 | 3.21 | 2.44 | -15.72% |
| Enterprise Value to EBITDA | -15.85 | -16.78 | -27.56 | -31.85 | -8.22% |
| Return on Equity | -20.0% | -19.6% | -16.2% | -16.3% | 0.90% |
| Total Debt | $0.73M | $0.62M | $0.66M | $0.65M | -14.87% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
